Joel Mases

Let’s talk about prostate and urethra contouring on MRI. Three recent 📄📄📄 @SeibertLab #radonc #ProstateCancer 🧵1️⃣ @IJROBP @RO_GreenJournal @ARRO_org @ASTRO_org @ESTRO_org

#EAU26 Congrats to the FASTRACK teams @_ShankarSiva. SBRT for RCC now has greater prospective data than all other ablative treatments and is a guideline supported SOC. Excited to continue to expand its use through the conduct of well designed clinical trials. Patients want a non-invasive option, but we must continue to generate these excellent results. @ASTRO_org @NCCN @NRGonc @ASCO

Someone suggested I make a table summarizing the video. Here it is!

#EAU26 Plenary Evidence from RCTs for MDT for oligorecurrent HSPC @urotoday

@jryckman3 @DrSpratticus @safaviaa @US_FDA This is our work. It’s the published series with the longest follow up. Moderate hypofractionation seems complety safe, and actually the highest toxicity profile for now seems with normofractionation at longest FU link.springer.com/article/10.100…

@jryckman3 @DrSpratticus @safaviaa @US_FDA Our group has recently published our experience. We have a long follow up, and though it seems safe at first to salvage (though our cohort was only cryo), we have detected very meaningful and grave long term toxicities, like a fistulae after 10y FU. Why focal first? Not worth.

Not sure who needs to hear this, but it is reasonable to ask whether a treatment being offered for cancer is actually approved for treating cancer. #OncTwitter

@jryckman3 @DrSpratticus @safaviaa @US_FDA link.springer.com/article/10.100…

If I had a nickel for every time a friend asked me about prostate focal therapy, I’d be rich. I’ve personally managed 20–30 intraprostatic failures after focal therapy. One patient ended up with a permanent Foley after salvage RT. Nearly all required medical castration, which many likely could have avoided with definitive therapy upfront. The downstream consequences are real. Our group ultimately decided not to offer focal therapy outside of very niche scenarios (for example select reirradiation not ideal for partial or full gland SBRT). If I were a patient, I might assume focal therapy is better than standard options too. The marketing is that good. #OncTwitter

ChemoRT works very well for MIBC. Low utilization rates have nothing to do with efficacy but on referral patterns and multiD buy in. Hard to shift dogma.

BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update. @BCLC_group @JHepatology 🔓journal-of-hepatology.eu/article/S0168-… #HCC #BCLC #LiverTwitter #LiverX

@Achard_Verane @MarioTerlizziFR @PaulSargos @BertrandTOMBAL @YssfGhannam @David__Pasquier Very interesting topic and a hot contentious discussion with my referal urologists! I always kindly ask them not to start STADT even if the indication is clear specifically for that. Btw, I think the link is not working…

When combining 6 mo ADT + RT: 👉 Start concurrently (per SANDSTORM)? 👉 Or begin with neoadjuvant ADT + repeat MRI? With up to 35% prostate shrinkage in 3 mo, timing is critical for DIL targeting & RT precision. Are we optimizing sequencing enough? sciencedirect.com/science/articl…

Absolutely remarkable that patients with urologic cancers can get 5 fractions of radiation or less and *reliably* delay systemic therapy for up to 2 years. Oligo SBRT is associated with minimal toxicity in many trials. People should talk about this way more often.

@Achard_Verane @BertrandTOMBAL @AmarUKishan @ZilliThomas I think PSMA-DC will for sure solve that question. Also, how much dose is needed to sustain a prolonged response? 2 cycles vs 4x Accumulated dosimetry would be so interesting to see. Neoadjuvant vs adjuvant. It may be practice changing.

Lessons learned from #LUNAR 🚀🌕, fantastic work by @AmarUKishan and colleagues 👏 : - MDT alone falls short in high-risk BCR - Lu-PSMA reaches beyond visible disease, but is it enough? sciencedirect.com/science/articl… @BertrandTOMBAL @ZilliThomas

That study is a danger for the patients...it just provides robust descriptive data on the burden of late GU toxicity among men presenting with complications after prostate RT, but offers weak and highly confounded evidence for any comparative treatment-effect conclusions.

@RicBertolo @EurUrolOncol @bernardorocco73 @minerviniandre @PaoloVerze @antopastl @lucacindolo @foxal72 @EAU_Uroonco @aleantonellibs1 @AgileGroupUro I’ve never seen a discussion that justifies than any contemporary treatment is toxic based on publications from 1991 and 1994. I’m quite sure you can all do better to justify an argument without incurring in such bias.

Miquel Puig guanyant aquest debat per golejada en els seus primers 60 segons.

Autèntic fan d'aquest noi que ha sortit ara al Telenotícies

@ggreen1986 @NiuSanford @HardenedBeam @OncoAlert I agree with the fastest complete response, but my experience with CR with SBRT at the explant has been amazing. And as you say, versatility, dose conformality, dose personalization and delivery makes SBRT hard to beat. It’s at least as good as (if not better, in many ways)

Yes I find small tumors <3cm y90 rad seg has faster complete response on imaging and better data for complete pathologic necrosis on transplant patients… however no question larger irregular tumors with MVI SBRT has an advantage. Personalized dosimetry is key… 400Gy to a pixel doesn’t matter need to look at voxel based dosimetry D95.

Radiation dose in SBRT vs. Y90 in HCC. This confused me for the LONGEST time. Both measured in Gy, but clearly not the same – Y90 doses often reach 400Gy+, SBRT doses much lower (<50 Gy), yet both efficacious. Explained below. Bottom line is Y90 Gy ≠ SBRT Gy. @OncoAlert

Hoy hemos recibido las peores de las noticias Nuestro querido compañero Jesús Saldaña ha fallecido en la catástrofe de Adamuz Todos lo recordamos con mucho amor. Era una persona excepcional y única que daba todo para los pacientes y todos sus compañeros. Que descanse en paz.

Hi everyone! Been a while, but back today with a teaching video on palliative RT for GI cancers. IMO palliative RT can be v effective, but is underutilized. Here is 13 min on indications, regimens, common q's re: palliative RT by GI site. Slides & full video link below 🧵1/5.